Dangers of Herpesvirus Infection in SLE Patients Under Anifrolumab Treatment: Case Reports and Clinical Implications
Open Access
- 29 July 2024
- journal article
- research article
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 25, e944505-e944505-7
Abstract
BACKGROUND Anifrolumab, a monoclonal antibody targeting the type 1 interferon (IFN-I) signaling pathway, holds promise as a therapeutic intervention for systemic lupus erythematosus (SLE). However, its use is associated with an increased risk of infections, particularly viral infections like herpes zoster (HZ). Results from the clinical trials on anifrolumab show yearly rates of upper respiratory tract infections of 34% and HZ of 6.1%. An increased frequency of other specific viral infections, including herpes simplex virus (HSV), was not reported. CASE REPORT Here, we present 2 cases of patients with SLE treated with anifrolumab, both experiencing severe adverse reactions in the form of disseminated herpesvirus infections, specifically disseminated HSV-2 and varicella zoster virus (VZV, HZ encephalitis). To the best of our knowledge, no previous reports of severe disseminated HSV-2 or HZ have been published in anifrolumab-treated patients. The patient in case 1 experienced a primary HSV-2 infection following anifrolumab treatment, potentially explaining the severity of the infection. The patient in case 2 had a history of previous HZ skin infections, which may have increased her risk of disseminated infection. Both patients recovered from the infections with minor sequelae, but they still require prophylactic antiviral treatment. These cases highlight the critical role of IFN-I immunity in protecting against herpesvirus infections. CONCLUSIONS Thorough risk assessment before anifrolumab initiation, considering the patient's viral infection history, vaccination status, and potential exposure risks, is essential. Administration of recombinant zoster vaccine before anifrolumab therapy may benefit susceptible individuals.Keywords
This publication has 42 references indexed in Scilit:
- A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)Annals of the Rheumatic Diseases, 2016
- Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older AdultsNew England Journal of Medicine, 2015
- Type I interferons in infectious diseaseNature Reviews Immunology, 2015
- Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation StudyArthritis & Rheumatism, 2013
- Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised studyAnnals of the Rheumatic Diseases, 2011
- Incidence, Risk Factors, and Outcome of Herpes Zoster in Systemic Lupus ErythematosusJCR: Journal of Clinical Rheumatology, 2010
- Fulminant hepatitis from herpes simplex virus type 2 in an immunocompetent adultTransplant Infectious Disease, 2007
- Herpes Simplex Virus Type 2 as a Cause of Severe Meningitis in Immunocompromised AdultsClinical Infectious Diseases, 2003
- Atypical presentation of herpes simplex virus in a patient with chronic lymphocytic leukemia.1999
- Characteristics of Autoantibodies to Human Interferon in a Patient with Varicella-Zoster DiseaseThe Journal of Infectious Diseases, 1984